Download this factsheet to learn more about tislelizumab, including approvals and regulatory filings, and pivotal clinical trials.

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more